Literature DB >> 18208579

The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study.

Jeannette Lee1, Derrick Heng, Stefan Ma, Suok-Kai Chew, Kenneth Hughes, E-Shyong Tai.   

Abstract

OBJECTIVE: This study assesses the effect of the metabolic syndrome on all-cause and cardiovascular disease (CVD) mortality in healthy Chinese, Malays and Asian Indians in Singapore. The utility of the metabolic syndrome is also compared with the Framingham risk score for prediction of mortality.
METHODS: Healthy participants (n = 5699) were grouped by the presence or absence of the metabolic syndrome, and followed up (mean 14.1 years) by data linkage with the National Death Register. Risk of mortality was obtained by Cox's proportional hazards model with adjusted hazard ratios (HRs). Area under receiver operating characteristic (ROC) curves were used to compare the metabolic syndrome and Framingham risk score for prediction of mortality.
RESULTS: During a follow-up of 80,236 person-years, there were 382 deaths, of which 128 were due to CVD. Individuals with the metabolic syndrome had an increased risk of mortality for 'all-causes' (males: HR 1.4, 95% confidence intervals (95%CI) 1.1-1.8; and females: HR 1.8, 95%CI 1.3-2.6). There was also an increased risk of mortality due to CVD (males: HR 3.0, 95%CI 1.9-4.8; and females: HR 2.1, 95%CI 1.1-4.0). The area under ROC for Framingham risk score was higher for both all-cause and CVD mortality than metabolic syndrome.
CONCLUSIONS: Although an increased risk of 'all-cause' and CVD mortality due to the metabolic syndrome was found, the Framingham risk function still performed better than the metabolic syndrome in an Asian population. However, the metabolic syndrome should not be disregarded as it is a clinically useful entity for identifying individuals for management of its component CVD risk factors.

Entities:  

Mesh:

Year:  2008        PMID: 18208579     DOI: 10.1111/j.1365-2265.2008.03174.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

2.  Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.

Authors:  Dor Mohammad Kordi-Tamandani; Mohammad Hashemi; Nooshin Sharifi; Mahmoud Ali Kaykhaei; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

3.  Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies.

Authors:  Sheng Hui Wu; Wu Sheng Hui; Zhong Liu; Suzanne C Ho
Journal:  Eur J Epidemiol       Date:  2010-04-28       Impact factor: 8.082

4.  Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore.

Authors:  Wai Man Mandy Chan; Yik Weng Yew; Thiam Seng Colin Theng; Choon Fong Liew; Hazel H Oon
Journal:  Singapore Med J       Date:  2019-12-02       Impact factor: 1.858

5.  Cardiovascular Risk Factors and Ethnicity Are Independent Factors Associated with Lower Urinary Tract Symptoms.

Authors:  Jasmine Lim; Nirmala Bhoo-Pathy; Selvalingam Sothilingam; Rohan Malek; Murali Sundram; Guan Hee Tan; Badrulhisham Bahadzor; Teng Aik Ong; Keng Lim Ng; Azad Hassan Abdul Razack
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

6.  Serum Adiponectin Levels and Their Association With Cardiometabolic Risk Factors in Patients With Psoriasis.

Authors:  Wai Sze Agnes Chan; Choon Fong Liew; Colin Thiam Seng Theng; Hazel H Oon
Journal:  Cureus       Date:  2020-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.